Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer
July 11 2017 - 7:00AM
Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company
engaged in the research and development of new medicines to treat
serious infections, with a focus on the pleuromutilin class of
antibiotics, today announced the appointment of Francesco Maria
Lavino as Chief Commercial Officer. He will report to Chief
Executive Officer Colin Broom, M.D. and be based out of the
company’s U.S. headquarters in King of Prussia, PA.
“Nabriva Therapeutics is on the cusp of a major inflection
point, as we work toward the potential approval of the first
pleuromutilin antibiotic for the treatment of community-acquired
bacterial pneumonia,” said Dr. Broom. “Francesco has the right
experience and leadership qualities to build out a fully integrated
commercial team and hospital field force in the United States, and
I am delighted to welcome him as part of our team.”
Mr. Lavino joins Nabriva Therapeutics from Merck & Co. Inc.,
bringing nearly two decades of pharmaceutical sales and marketing
experience. The last half of his career has been focused on
anti-infective medications administered primarily in the hospital
setting. Mr. Lavino joins the company ahead of the conclusion of
its Phase 3 global clinical trials for lefamulin, a potential new
treatment for community-acquired bacterial pneumonia. If lefamulin
is approved in the United States, Mr. Lavino will be responsible
for enabling doctors to have access and treat those patients who
would benefit from lefamulin. Mr. Lavino will be supported by Will
Sargent, Vice President, Commercial Strategy. Nabriva owns
exclusive, worldwide rights to lefamulin and Mr. Lavino will also
support Nabriva’s business development activities to explore
potential commercialization opportunities outside the U.S.
“There has been a dearth of innovation in the development of new
anti-infective medicines,” said Mr. Lavino. “Nabriva Therapeutics
is poised to introduce what is potentially the first new class of
antibiotics for systemic human use in nearly two decades. I am
looking forward to working with Will, Colin and the rest of the
management team to address serious medical needs in lung, skin, and
potentially other types of infections.”
Mr. Lavino has held positions of increasing responsibility at
Merck & Co. Inc. (known as MSD outside the United States), most
recently serving as AVP, Global Brand Leader Anti-Infective
Portfolio responsible for the development and implementation of the
global marketing strategy for the entire Merck anti-bacterial
portfolio. Prior to this role he was VP International Marketing for
the Anti-Infectives Portfolio at Cubist Pharmaceuticals. Previous
roles at Merck included Executive Director, Global Brand Leader,
for the company’s antifungal medicines Cancidas® (caspofungin
acetate) and Noxafil® (posaconazole) and, before, he held positions
both at regional and country level in marketing and sales. Mr.
Lavino began his career in pharmaceutical sales at UCB Pharma and
3M in Italy.
About Nabriva Therapeutics plcNabriva
Therapeutics is a biopharmaceutical company engaged in the research
and development of new medicines to treat serious bacterial
infections, with a focus on the pleuromutilin class of antibiotics.
Nabriva Therapeutics’ medicinal chemistry expertise has enabled
targeted discovery of novel pleuromutilins, including both
intravenous and oral formulations. Nabriva Therapeutics’ lead
product candidate, lefamulin, is a novel semi-synthetic
pleuromutilin antibiotic with the potential to be the
first-in-class available for systemic administration in humans. The
company believes that lefamulin is the first antibiotic with a
novel mechanism of action to have reached late-stage clinical
development in more than a decade. Lefamulin is currently being
evaluated in two global, registrational Phase 3 clinical trials in
patients with moderate to severe community-acquired bacterial
pneumonia (CABP). Nabriva Therapeutics believes lefamulin is
well-positioned for use as a first-line empiric monotherapy for the
treatment of moderate to severe CABP due to its novel mechanism of
action, targeted spectrum of activity, resistance profile,
achievement of substantial drug concentration in lung tissue and
fluid, oral and IV formulations and a favorable tolerability
profile. Nabriva Therapeutics intends to further pursue development
of lefamulin for additional indications, including the treatment of
acute bacterial skin and skin structure infections (ABSSSI), and is
developing a formulation of lefamulin appropriate for pediatric
use.
Nabriva Therapeutics owns exclusive, worldwide rights to
lefamulin, which is protected by composition of matter patents
issued in the United States, Europe and Japan.
CONTACT:
INVESTOR RELATIONS
Dave Garrett
Nabriva Therapeutics plc
david.garrett@nabriva.com
610-816-6657
MEDIA
Benjamin Navon
Pure Communications, Inc.
bnavon@purecommunications.com
617-337-4166
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Sep 2023 to Sep 2024